Association rules statistics of HLA-I (A, B, and C) combinations of Mel and STS patients who received DCV immunotherapy
Lhs1
Rhs2
Support
Confidence
Cov3
Lift
Count4
1
HLA-B*13
HLA-C*06
0.0598
1.0000
0.0598
4.000
1
2
HLA-B*52
HLA-C*12
0.0598
1.0000
0.0598
4.182
11
3
HLA-A*25
HLA-B*18
0.0543
0.7692
0.0707
4.423
10
4
HLA-A*25
HLA-C*12
0.0597
0.8462
0.0707
3.538
11
5
HLA-B*14
HLA-C*08
0.0598
0.9167
0.0652
10.542
11
6
HLA-B*57
HLA-C*06
0.0924
1.0000
0.0923
4.000
17
7
HLA-B*08
HLA-A*01
0.0924
0.7727
0.1196
3.3852
17
8
HLA-B*08
HLA-C*07
0.1196
1.0000
0.1196
2.0909
22
9
HLA-B*40
HLA-C*03
0.0978
0.7200
0.1358
3.5805
18
10
HLA-B*35
HLA-C*04
0.1413
0.9286
0.1522
4.4962
26
11
HLA-B*07
HLA-C*07
0.1902
0.9459
0.2010
1.9779
35
12
HLA-B*18, HLA-A*25
HLA-C*12
0.0543
1.0000
0.0543
4.1818
10
13
HLA-C*12, HLA-A*25
HLA-B*18
0.0543
0.9091
0.0598
5.2273
10
14
HLA-B*57, HLA-A*01
HLA-C*06
0.0597
1.0000
0.0598
4.0000
11
15
HLA-B*08, HLA-A*01
HLA-C*07
0.0923
1.0000
0.0924
2.0909
17
16
HLA-B*08, HLA-C*07
HLA-A*01
0.0924
0.7727
0.1196
3.3853
17
17
HLA-C*07, HLA-A*01
HLA-B*08
0.0924
0.8095
0.1141
6.7706
17
18
HLA-B*40, HLA-A*02
HLA-C*03
0.0543
0.7692
0.0707
3.8254
10
19
HLA-B*18, HLA-A*02
HLA-C*07
0.0598
0.7333
0.0815
1.5333
11
20
HLA-B*07, HLA-A*02
HLA-C*07
0.0924
1.0000
0.0924
2.0909
17
1 Lhs is left-hand-side or X in the association rule; 2 Rhs is right-hand-side or Y in the association rule; 3 Coverage is a proportion of observations in the full dataset that comply with the rule; 4 Count of the observations with the rule. Mel: melanoma; STS: soft tissue sarcomas; DCV: dendritic cell vaccine
TLN: Supervision, Project administration, Validation. AVN: Conceptualization, Data curation, Software. DVG: Formal analysis, Methodology, Visualization. ABD: Writing—review & editing, Validation. PAS: Writing—original draft, Data curation. AVG and MAN: Resources, Investigation. NAE: Writing—review & editing, Data curation. AVO: Data curation, Formal analysis. IAB: Project administration, Validation. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The study was approved by the ethics committee of the N.N. Petrov National Medical Research Center of Oncology Protocol No. 2 dated 20.02.2020.
Consent to participate
Informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
The datasets for this manuscript are not publicly available, since informed consent was not obtained from the participants for data sharing with third parties. Requests for access to the aggregated data from the study datasets should be directed to the corresponding author.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, et al. Trial watch: dendritic cell vaccination for cancer immunotherapy.Oncoimmunology. 2019;8:e1638212. [DOI] [PubMed] [PMC]
Meng X, Sun X, Liu Z, He Y. A novel era of cancer/testis antigen in cancer immunotherapy.Int Immunopharmacol. 2021;98:107889. [DOI] [PubMed]
Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy.Exp Hematol Oncol. 2022;11:3. [DOI] [PubMed] [PMC]
Liu Z, Gao C, Tian J, Ma T, Cao X, Li A. The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma: A meta-analysis of randomized controlled studies.Neurochirurgie. 2021;67:433–8. [DOI] [PubMed]
Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, Wang X, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis.Cytotherapy. 2018;20:975–89. [DOI] [PubMed]
Mohammadzadeh M, Shirmohammadi M, Ghojazadeh M, Nikniaz L, Raeisi M, Aghdas SAM. Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis.Prostate Int. 2018;6:119–25. [DOI] [PubMed] [PMC]
Handy CE, Antonarakis ES. Sipuleucel-T for the Treatment of Prostate Cancer: Novel Insights and Future Directions.Future Oncol. 2018;14:907–17. [DOI] [PubMed] [PMC]
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.N Engl J Med. 2010;363:411–22. [DOI] [PubMed]
Kumar C, Kohli S, Chiliveru S, Bapsy PP, Jain M, Suresh Attili VS, et al. A Retrospective Analysis Comparing APCEDEN® Dendritic Cell Immunotherapy with Best Supportive Care in Refractory Cancer.Immunotherapy. 2017;9:889–97. [DOI] [PubMed]
Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.J Transl Med. 2018;16:142. [DOI] [PubMed] [PMC]
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research (REGATA) [Internet].N.N. Petrov NMRC of Oncology; c2022 [cited 2024 Dec 1]. Available from: https://www.clinicaltrials.gov/study/NCT05539677
Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, et al. Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients.Vopr Onkol. 2012;58:212–21. Russian. [PubMed]
Baldueva IA, Danilova AB, Nekhaeva TL, Avdonkina NА, Emelyanova NV, Belyaev AM, inventor. Cell product for loading and activation of human dendrite cells.Russian Federation patent RU 2714208. 2020 Feb 13.
Danilova A, Misyurin V, Novik A, Girdyuk D, Avdonkina N, Nekhaeva T, et al. Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells.Clin Sarcoma Res. 2020;10:3. [DOI] [PubMed] [PMC]
Nishino M. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond.Am Soc Clin Oncol Educ Book. 2018;38:1019–29. [DOI] [PubMed]
Iannessi A, Beaumont H, Liu Y, Bertrand AS. RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?Insights Imaging. 2021;12:36. [DOI] [PubMed] [PMC]
Goyal S, Sakhi P, Kalidindi S, Nema D, Pakhare AP. Knowledge, Attitudes, Perceptions, and Practices Related to Artificial Intelligence in Radiology Among Indian Radiologists and Residents: A Multicenter Nationwide Study.Cureus. 2024;16:e76667. [DOI] [PubMed] [PMC]
Therneau TM, Lumley T, Elizabeth A, Cynthia C. survival: Survival Analysis. R package version 3.8-3. 2024. [DOI]
Kassambara A, Kosinski M, Biecek P, Fabian S. Survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.5.0. 2024. [DOI]
Hahsler M, Grün B, Hornik K. A Computational Environment for Mining Association Rules and Frequent Item Sets.Journal of Statistical Software. 2005;14:1–25. [DOI]
Liu D, Che X, Wang X, Ma C, Wu G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.Pharmaceuticals (Basel). 2023;16:1384. [DOI] [PubMed] [PMC]
Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease.Nat Rev Immunol. 2018;18:325–39. [DOI] [PubMed]
Georgopoulos AP, James LM, Sanders M. Nine Human Leukocyte Antigen (HLA) Class I Alleles are Omnipotent Against 11 Antigens Expressed in Melanoma Tumors.Cancer Inform. 2024;23:11769351241274160. [DOI] [PubMed] [PMC]
Lee CH, DiNatale RG, Chowell D, Krishna C, Makarov V, Valero C, et al. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Mol Cancer Res. 2021;19:1510–21. [DOI] [PubMed] [PMC]
Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification.BMC Immunol. 2008;9:1. [DOI] [PubMed] [PMC]
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, et al. Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.J Immunol. 2024;213:23–8. [DOI] [PubMed] [PMC]
Gonzalez-Galarza FF, McCabe A, Melo Dos Santos EJ, Ghattaoraya G, Jones AR, Middleton D. Allele Frequency Net Database.Methods Mol Biol. 2024;2809:19–36. [DOI] [PubMed]
Dhall A, Patiyal S, Kaur H, Bhalla S, Arora C, Raghava GPS. Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics.Front Genet. 2020;11:221. [DOI] [PubMed] [PMC]
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science. 2018;359:582–7. [DOI] [PubMed] [PMC]
Rosenbaum E, Seier K, Bandlamudi C, Dickson M, Gounder M, Keohan ML, et al. HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome.Clin Cancer Res. 2020;26:5448–55. [DOI] [PubMed] [PMC]
Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, et al. HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.Tissue Antigens. 2011;78:203–7. [DOI] [PubMed]
Aboulaghras S, Khalid A, Makeen HA, Alhazmi HA, Albratty M, Mohan S, et al. Polymorphism of HLA and Susceptibility of Breast Cancer.Front Biosci (Landmark Ed). 2024;29:55. [DOI]
Abed A, Reid A, Law N, Millward M, Gray ES. HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy.Cancers (Basel). 2024;16:3102. [DOI] [PubMed] [PMC]
